Aalberts: Preview - steady in difficult markets. ABN AMRO: 1Q24 overshadowed by weaker capital, even if a strong set. AEGON: 1Q24 Preview (trading update). Alfen: Preview - clarity on one-off Pacto costs crucial. B&S Group: Bolt-on acquisition in Personal Care. Belgian telcos: BIPT notes that fibre cooperation negotiations not ready by 15 May. EVS: 1Q24 preview. Euronext: Another record, with Beats by Boujnah. Montea: €12m acquisition in the Port of Ghent. Staffing: Dutch Perio...
>Mainly qualitative information, only two numbers to be provided - Aalberts will provide a mainly qualitative trading update on May 22nd at 07.30. No analyst call is planned although we will see Aalberts’ management that day as they are present at our ABN AMRO Benelux conference. The trading update will, normally, contain two numbers: orderbook growth versus the same period last year and organic growth. In addition, Aalberts will say something about its value add, op...
>Operating results in line, higher financial costs weigh on net profits - Results are in line with our estimates (EBITDA -2.3% y-o-y) reflecting a lower contribution from the domestic business due to the decrease in assets and opex remuneration and an increase in opex (core opex +1.6% y-o-y) and stable performance from the international business. Net results are additionally affected by higher financial expenses (2.8% vs 2.4% in Q1 2023) and unfavourable exchange rate...
PARIS--(BUSINESS WIRE)-- Regulatory News: Par contrat en date du 3 novembre 2023 la société Carmila SA (Paris:CARM) a confié à Kepler Cheuvreux la mise en œuvre d’un Contrat de Liquidité. Ce Contrat de Liquidité, doté d’un montant initial de 124 528 Actions et 971 454,65 Euros, renouvelable annuellement par tacite reconduction, a pour objet l'animation des actions de la société Carmila SA (ISIN : FR0010828137) sur le marché réglementé de Euronext Paris. Afin de réajuster l’enveloppe mise à disposition de ce contrat, il a été procédé, en date du 07/05/2024, à un retrait de 78 000 Actions ...
Unifiedpost is a niche SaaS player in the e-invoicing and procurement channel space. Regulatory headwinds mean this market is ripe for growth, which should benefit Unifiedpost. Due to some unsuccessful past M&A, the company is in a challenging financial position today. However, it has recently embarked on a divestment path, aiming to streamline the business and improve its fundamentals. We like the new direction, however prefer to take a wait-and-see approach. - ...
Unifiedpost is a niche SaaS player in the e-invoicing and procurement channel space. Regulatory headwinds mean this market is ripe for growth, which should benefit Unifiedpost. Due to some unsuccessful past M&A, the company is in a challenging financial position today. However, it has recently embarked on a divestment path, aiming to streamline the business and improve its fundamentals. We like the new direction, however prefer to take a wait-and-see approach. - ...
>Good Q1 2024 results - Montana Aerospace has just released a good set of Q1 2024 results. Adjusted EBITDA was reported at € 38.2m on sales of € 396m leading to a margin of 9.7% (vs 6.7% the previous year). This performance was mainly driven by Aerostructures which reported an adjusted EBITDA of € 29.4m on sales of € 207.8m leading to a margin expansion to 14.1% vs 9.1% in Q1 2023 (despite supply chain issues challenges within at ASCO). However, the E-Mobility busine...
>Good Q1 2024 results - Montana Aerospace has just released a good set of Q1 2024 results. Adjusted EBITDA was reported at € 38.2m on sales of € 396m leading to a margin of 9.7% (vs 6.7% the previous year). This performance was mainly driven by Aerostructures which reported an adjusted EBITDA of € 29.4m on sales of € 207.8m leading to a margin expansion to 14.1% vs 9.1% in Q1 2023 (despite supply chain issues challenges within at ASCO). However, the E-Mobility busine...
PARIS--(BUSINESS WIRE)-- Regulatory News: CE COMMUNIQUE DE PRESSE N'EST PAS DIFFUSE ET DES COPIES NE PEUVENT PAS ETRE DISTRIBUEES OU ENVOYEES, DIRECTEMENT OU INDIRECTEMENT, AUX ETATS-UNIS, AU CANADA, EN AFRIQUE DU SUD, AU JAPON OU EN AUSTRALIE. GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, éligible PEA-PME) (la "Société"), une Société biopharmaceutique spécialisée dans le développement et la commercialisation de thérapies géniques innovantes pour les maladies neurodégénératives de la rétine et les troubles du système nerveux central, a annoncé aujourd'hui la mise à disposition d...
PARIS--(BUSINESS WIRE)-- Regulatory News: GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, éligible PEA-PME), société biopharmaceutique dédiée au développement et à la commercialisation de thérapies géniques innovantes pour le traitement des maladies neurodégénératives de la rétine et du système nerveux central, annonce la tenue de son Assemblée Générale Mixte le 29 mai 2024 à 9h00 au siège social de la Société, 74 rue du Faubourg Saint-Antoine, 75012 Paris, France. L’Assemblée Générale sera également retransmise en direct pour les actionnaires sur le site Internet de la Société ...
PARIS--(BUSINESS WIRE)-- Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced that it will hold its Annual General Meeting on May 29, 2024, at 9:00 am CEST at the Company’s headquarters, 74 rue du Faubourg Saint-Antoine, 75012 Paris, France. The General Meeting will also be webcast live for shareholders on the Company’s website (). The notice containing the agenda and draft re...
PARIS--(BUSINESS WIRE)-- Regulatory News: CARMILA (Paris:CARM): Date Nombre d’actions composant le capital social Nombre réel de droits de vote (déduction faite des actions auto-détenues) Nombre théorique de droits de vote (y compris les actions auto-détenues)* 30 avril 2024 142 441 073 142 256 845 142 441 073 *en application de l’article 223-11 du Règlement général de l’Autorité des marchés financiers. Fait à Paris, le 7 mai 2024. CARMILA Société anonyme au capital de 854.646.438 euros Siège social : 25, rue d’Astorg, 75008 Paris RC...
>Visibility out to the second part of Q3 2024 - The company has announced a capital increase of € 9.2m through issuing ABSA (Shares with warrants) at a price of € 0.395 per share, giving a discount of c.2%. The exercise price of the share subscription warrants is set at € 0.45, giving a premium of c.13%. In the case of the exercise of warrants, the dilution would be c.37%. Note that over 50% of the offering has been subscribed to by US investors such as Armistice Capi...
>Visibilité jusqu’à la deuxième partie du T3 2024 - La société annonce la réalisation d’une augmentation de capital de 9.2 M€ via l’émission d’ABSA au prix de 0.395 € par ABSA soit une décote de c. 2%. Le prix d’exercice des BSA est fixé à 0,45 € soit une prime de c. 13%. En cas d’exercice des BSA la dilution serait de c. 37%. Notons que plus de 50% de l’offre a été souscrite par des investisseurs américains dont Armistice Capital et JEA Vision.GenSight envisage...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.